CYYNF (Cynata Therapeutics) Retained Earnings: $-62.71 Mil (As of Dec. 2025)


What is Cynata Therapeutics Retained Earnings?

Cynata Therapeutics CYYNF Retained Earnings is $-62.71 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Cynata Therapeutics's retained earnings for the quarter that ended in Dec. 2025 was $-62.71 Mil.

Cynata Therapeutics's quarterly retained earnings declined from Dec. 2024 ($-54.45 Mil) to Jun. 2025 ($-59.71 Mil) and declined from Jun. 2025 ($-59.71 Mil) to Dec. 2025 ($-62.71 Mil).

Cynata Therapeutics's annual retained earnings declined from Jun. 2023 ($-48.71 Mil) to Jun. 2024 ($-54.66 Mil) and declined from Jun. 2024 ($-54.66 Mil) to Jun. 2025 ($-59.71 Mil).

Cynata Therapeutics  (OTCPK:CYYNF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Cynata Therapeutics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Cynata Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cynata Therapeutics Retained Earnings Chart

Cynata Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -40.41 -40.97 -48.71 -54.66 -59.71

Cynata Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -51.62 -54.66 -54.45 -59.71 -62.71

Cynata Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-62.71 Mil mean?
Cynata Therapeutics (CYYNF) has a Retained Earnings of $-62.71 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Cynata Therapeutics and its competitors.
Is Cynata Therapeutics' Retained Earnings too high?
Cynata Therapeutics' current Retained Earnings is $-62.71 Mil.
How does Cynata Therapeutics' Retained Earnings compare to VRTX and REGN?
Cynata Therapeutics' Retained Earnings of $-62.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Cynata Therapeutics and its competitors. Cynata Therapeutics's current Retained Earnings is $-62.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cynata Therapeutics stock overvalued right now?
Cynata Therapeutics (CYYNF) has a current Retained Earnings of $-62.71 Mil. The current Retained Earnings is $-62.71 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Cynata Therapeutics (CYYNF), the current Retained Earnings is $-62.71 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cynata Therapeutics Business Description

Other Exchanges 51S:GermanyCYP:Australia
Address 100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus manufacturing platform. There are currently three active clinical trials taking place using Cymerus technology, which are attempting to treat osteoarthritis and others.